Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | BLM | P54132 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CAD | P27708 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.35 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.31 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1650778 | 0.98 | — | — | |
| SCHEMBL6998150 | 0.98 | — | — | |
| SCHEMBL756341 | 0.98 | — | — | |
| SCHEMBL6186602 | 0.80 | — | — | |
| SCHEMBL28763835 | 0.80 | — | — | |
| SCHEMBL890128 | 0.80 | — | — | |
| SCHEMBL890097 | 0.80 | — | — | |
| SCHEMBL1745137 | 0.78 | CYP2D6 (0.36) | CYP2D6LMNABLMALOX15CYP1A2 | |
| Lithium Ion SCHEMBL17224576 | 0.78 | — | — | |
| SCHEMBL1745139 | 0.78 | CYP2D6 (0.36) | CYP2D6LMNABLMALOX15CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114031572-A | Process for preparing substituted cycloserines | 先正达参股股份有限公司 | 2022-02-11 | — | — | CN | disclosed |
| US-9815803-B2 | Process for the preparation of substituted cycloserines | SYNGENTA PARTICIPATIONS AG (CH) | 2017-11-14 | — | — | US | disclosed |
| US-20170204072-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED CYCLOSERINES | SYNGENTA PARTICIPATIONS AG (CH) | 2017-07-20 | — | — | US | disclosed |
| US-9643938-B2 | Process for the preparation of substituted cycloserines | SYNGENTA PARTICIPATIONS AG (CH) | 2017-05-09 | — | — | US | disclosed |
| EP-3137449-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED CYCLOSERINES | Syngenta Participations AG (CH) | 2017-03-08 | — | — | EP | disclosed |
| US-20170044116-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED CYCLOSERINES | SYNGENTA PARTICIPATIONS AG (CH) | 2017-02-16 | — | — | US | disclosed |
| WO-2015166094-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED CYCLOSERINES | SYNGENTA PARTICIPATIONS AG (CH) | 2015-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044116-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED CYCLOSERINES | C1S, C1R, C5 | CYP2D6 407/4885LMNA 2991/4885BLM 4430/4885 |
| US-20170204072-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED CYCLOSERINES | C1S, C1R, C5 | CYP2D6 332/4885LMNA 2889/4885BLM 4345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.